Abstract Steroid hormones and their nuclear receptors play a major role in the development and progression of breast cancer. MCF-7 cells are triple-positive breast cancer cells expressing estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). However, interaction and their role in expression pattern of activator protein (AP-1) transcription factors (TFs) are not completely understood. Hence, in our study, MCF-7 cells were used as an in vitro model system to study the interplay between the receptors and hormones. MCF-7 cells were treated with estradiol-17b (E2), progesterone (P4), and dexamethasone (Dex), alone or in combination, to study the proliferation of cells and expression of AP-1 genes. MTT assay results show that E2 or P4 induced the cell proliferation by more than 35 %, and Dex decreased the proliferation by 26 %. E2 and P4 are found to increase ERa by more than twofold and c-Jun, c-Fos, and Fra-1 AP-1 TFs by more than 1.7-fold, while Dex shows opposite effect of E2-or P4-induced effect as well as effect on the expression of nuclear receptors and AP-1 factors. E2 antagonist Fulvestrant (ICI 182,780) found to reduce proliferation and E2-induced expression of AP1-TFs, while P4 or Dex antagonist Mifepristone (RU486) is found to block GRmediated expression of NRs and AP-1 mRNAs. Results suggest that E2 and P4 act synergistically, and Dex acts as an antagonist of E2 and P4.
Introduction
Mammary glands are the modified sweat glands developed in females during and after puberty. Development of mammary gland takes place under the influence of steroid hormones, the estrogen and progesterone produced by the ovary. The luminal epithelium of the gland contains receptors for steroid hormones, and sequential activation of hormonal signaling in the mammary epithelium is required for the progression of morphogenesis [1] . The steroid hormones in cooperation with pituitary hormones play a major role in the induction of proliferation and differentiation of epithelial and stromal cells leading ultimately to the formation of ductal and alveolar structures during the development of mammary gland [2] . Over-expression of these reproductive hormones and their receptors leads to an uncontrolled division of breast epithelial cells and metastasis, causing breast cancer. Most of the breast cancer cases are triple positive (ER, PR, and GR positive), and hence it is important to know the role of each of these steroid hormones, mechanism of their action, and expression of these receptors in breast cancer.
Steroid hormone receptors belong to a nuclear receptor super-family of proteins. They are sequestered in cytosol as an inactive complex by binding to heat-shock proteins (Hsps); upon binding to ligand or hormone, the steroid receptor separates from Hsps, hormone-receptor complex dimerizes and translocates into the nucleus, binds to specific regions of DNA, and transactivates the target genes [3] . The receptors that lack AF-2 domain fail to recognize HREs and hence do not mediate genomic pathways involved in the expression of ligand-mediated responses. However, steroid hormones also show nongenomic actions that involve the membrane-associated receptor binding, and activate second messengers, which in turn transactivate the cascade pathway involving protein kinases (PKA or PKC or PKB, MAPK, PI3K, Src kinases, EGF, etc.) [4] . ER, the classical steroid receptor, mainly exists as ERa or ERb, and ERa-containing AF-2 element recruits p-160 coregulatory protein involved in recognizing estrogen response elements (EREs) in the promoter region of the target DNA. GR exists as GRa and GRb. GRa, like the classical steroid receptor, lies in the cytoplasm as a complex, binding to Hsps; upon binding of ligand glucocorticoid (GC), GRa is separated from Hsps and forms complex with GC, which is then translocated and binds to GRE in the nucleus and brings about activation of genes. Whereas, GRb lacks LBD and hence cannot bind to hormone GC. PR exists as PRa and PRb isoforms. Unlike ER and GR, both the isoforms of PR are involved in tumorigenesis of breast epithelial cells as they are transcribed from the same gene via alternative promoter usage. Like ER and GR, PR isoforms also function as ligand-dependent transcription factors [5] .
In HRE-independent genomic pathway, hormone-receptor dimer will not bind to hormone response element (HRE), instead it will bind to HRE-like sites which serve as orphan hormone binding sites, and the mechanism of action involves the tethering of hormonal receptors to other DNAbinding transcription factors (TFs), such as AP-1 or NFjB, and transcription of gene occurs. Activator protein-1 (AP-1) plays a critical role in the regulation of breast cells proliferation as well as in the development of cancer. AP-1 TFs contain basic leucine zipper (bZIP) domain required for DNA-ligand dimer formation and regulate various cellular processes. They represent sequence-specific DNAbinding transcription factors and consist of homo-or heterodimers, which are formed by either homodimer of JunJun (c-Jun, Jun-B, Jun-D), or Jun-Fos heterodimer (Jun-cFos/Fra-1/Fra-2), or activating transcription factor (ATF) proteins, in mammalian cells [6] . Various combinations of Jun/Jun or Jun/Fos proteins regulate different cellular processes such as proliferation, differentiation, and angiogenesis.
Studies show that in the case of ERE-independent genomic pathway, Estradiol-17b-AP1 complex found to induce the expression of c-Jun and Cyclin D1 through ERSp1 complex which in turn depends on the type of ligand, the cell type, and also the receptor sub-types. It is also proved that the specific residues in the second zinc finger motif of ERb-DBD discriminate between classical mechanism of ER action and modulation of AP-1 and signal transducer and activator of transcription (STAT-5) activities through tethering. These specific residues in the second structure of zinc finger DBD region of ER were found to be involved in the GR-mediated repression of AP-1 activity [7] .
Like estrogen, the progesterone and glucocorticoids also act as the key regulators of proliferation, differentiation, and development of breast cancer. However, the effect of GC depends on the E2 concentration and the expression of ERa in breast tumor cells. Studies using in vitro model system show that GC inhibits the growth of ERa-positive cells [8] . Estrogens and glucocorticoids have opposing effects on the expression of respective nuclear receptor mRNAs and specific AP-1 factors. AP-1 was found to be upregulated by E2, while GC down-regulates the same when acting simultaneously with E2 [9] . Similarly, GC and mineralocorticoid (MC) cross-talk with PR to produce progesterone-like effects in breast cancer cells. Although GR and PR share some overlapping activity in mediating local adhesion, their cross-talk effects in regulating cell proliferation were found to be varied [10] .
Fulvestrant (ICI 182,780) is a pure potent antagonist of E2 that binds to ER in a competitive inhibitory manner. When ICI 182,780 binds to ER, the receptor dimerization is impaired with the energy-dependent nucleocytoplasmic shuttling, which occurs and blocks the nuclear localization of the receptor [11] . Thus, ICI exerts selective estrogen receptor down-regulation (SERD) with anti-proliferative activity and induction of apoptosis. The ICI-ER complex makes ER unavailable and unresponsive towards E2, and thereby ER proteins are degraded, and hence the transcription of ER-targeted genes are down-regulated [12] . The binding of ICI 182,780 is different from that of ERTamoxifen as it may act as E2 agonist or antagonist [13] . The degradation of ER protein by ICI leads to the complete inhibition of E2-mediated signaling through ER [12] . Mifepristone (RU486) is a synthetic 19-norsteroid and is a potent antagonist of progesterone and also glucocorticoids. In our studies, we used ICI 182,780 and RU486 to inhibit the specific action of E2, GC, and P4 on the expression of genes in MCF-7 cells.
Different types of adenocarcinoma cells show variable pattern of mRNA expression of hormone receptors and AP-1 TFs. Earlier studies carried out in our laboratory show the differential expression pattern of ERa and AP-1 TFs, in both ERa-responsive positive breast cancer cells (MCF-7) and ERa-nonresponsive lung epithelial cells (A549). In MCF-7 cells, E2 induced cell proliferation and proliferative genes such as ERa, c-Jun, Fra-1 and Fra-2 AP-1 TFs. Whereas, Tamoxifen, used as antagonist of E2, found to down-regulate the expression of ERa as well as Jun and Fos AP-1 TFs, showing that ERa-positive cells in a breast tumor respond to tamoxifen treatment. Since, ER-nonresponsive lung adenocarcinoma cells do not express ER, the ER-mediated proliferation of cells was not observed. However, AP-1 TFs were expressed independent of ER in A549 cells [14, 15] . In spite of such several studies, the mechanism and cross-talk between ER, PR, and GR, and their role in the regulation of expression of AP-1 factors in breast cancer etiology remain unclear. Hence, the present study was undertaken to use the analogues of steroid hormones (Estradiol-17b, Progesterone, and Dexamethasone) and specific antagonists to modulate specific receptors expression and the cross-talk between different steroid hormone receptors. Further, the role of steroid receptors and their hormones and the expression pattern of AP-1 factors were studied using triple-positive MCF-7 cells as a model system under in vitro conditions.
Materials and methods

Materials
Human breast cancer cells (MCF-7) were purchased from NCCS (Pune, India); Estradiol-17b, Progesterone, Dexamethasone, Fulvestrant (ICI 182, 780), Mifepristone (RU486), forward and reverse primers for ERa, ERb [14] , different AP-1 factors [15] , and PR and GR were purchased from Sigma-Aldrich (St Louis, USA). Superscript reverse transcriptase for RT-PCR was purchased from Invitrogen (CA, USA). RPMI 1640 media, fetal bovine serum (FBS), penicillin, streptomycin, glutamine, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), Sodium Pyruvate, and Trypan blue dye were purchased from Himedia (Mumbai, India). Antibody to GAPDH was purchased from NeoBiolab (MA, USA), and anti-rabbit antibody-HRP conjugate was purchased from Imgenex India Pvt. Ltd. (Bhubaneswar, India). Antibody to ERa was a generous gift from Prof. A. J. Rao, PR and anti-mouse antibody-HRP conjugate were gifts from Prof. Anjali Karande, Indian Institute of Science, Bengaluru, India. Taq DNA polymerase (1 U/ll) and Luminata Forte Western HRP substrate were procured from Merck-Millipore (Mumbai, India).
Culturing of MCF-7 cells and treatment
MCF-7 cells were grown in 75 cm 2 culture flask in RPMI 1640 media with 10 % FBS, 100 U/ml penicillin, 100 lg/ ml streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate. Cells were cultured in a humidified atmosphere at 37°C by passing 5 % CO 2 in an incubator. Flask containing 90-100 % confluent cells were sub-cultured in 96-well plate (3 9 10 3 cells/well) or in 6-well plate (5 9 10 5 cells/well) for the treatment with different modulators.
MTT assay
MTT assay for cell viability was carried out as per the protocol described earlier [16] . In brief, MCF-7 cells (3 9 10 3 cells/well) in 200 ll of RPMI 1640 media were seeded into 96-well culture plate and incubated overnight at 37°C with the supply of 5 % CO 2 . Cells were treated with or without different concentrations of E2 (10-1000 nM), or P4 (10-1000 nM), or Dex (10-500 lM), or ICI 182,780 (10-100 nM), or RU486 (10-1000 nM), incubated for 48 h, washed with PBS, treated with 20 ll of MTT (5 mg/ml), and incubated further for 4 h at 37°C with the supply of 5 % CO 2 in an incubator. Live cells take up the yellow compound MTT, and mitochondrial enzymes reduce it to insoluble blue formazan products which were dissolved in DMSO (100 ll), and absorbance was measured at 540 nm using spectrophotometer. The effect of E2 or Dex or P4 or ICI 182,780 and RU486 on cell viability was calculated and represented graphically as % of viable cells compared to control.
RNA isolation and semi-quantitative PCR
Overnight cultured MCF-7 cells (5 9 10 5 cells/well) in a 6-well plate were treated with or without E2 (100 nM), or Dex (100 nM), or P4 (150 nM) or E2 (100 nM) and Dex (100 nM) or P4 (150 nM) and Dex (100 nM) or E2 (100 nM) and P4 (150 nM) or E2 (100 nM) and Dex (100 nM) and P4 (150 nM) or E2 (100 nM) and ICI 182,780 (10 nM) or Dex (100 nM) and RU486 (10 nM), or P4 (150 nM) and RU486 (10 nM) for 48 h. Total RNA was isolated from each of the samples using ''Trizol reagent'' and as per the instructions provided by the manufacturer. Reverse transcription of RNA and PCR analysis was carried out as per the protocol described earlier [17] . In brief, total RNA (2 lg) was reverse transcribed using Oligo (dT) primers and superscript reverse transcriptase. The cDNA was subjected to 30 cycles of PCR using different forward and reverse primers of nuclear receptors (NRs) or AP-1 factors using appropriate annealing temperatures as indicated earlier [14] and in Table 1 in a gradient Eppendorf thermocycler. Amplified PCR products were analyzed on 1 % agarose gel using 19 TAE buffer. Relative mRNA levels were quantified using image analysis software (ImageJ). The expression of b-actin mRNA was used as a positive control and for normalization.
Immunoblotting of ERa and PR
Total protein of MCF-7 cell extracts was prepared and analyzed by western blotting as per the protocol described earlier [17] . Control and treated cells seeded in a 6-well plate were washed thrice with PBS followed by the addition of 0.2 ml of cold lysis buffer [Tris-HCl (50 mM) pH 8.0, NaCl (150 mM), NP-40 (1.0 %), and PMSF (100 lM)]. Cells were scraped, and suspensions were gently transferred to the pre-cooled Eppendorf tubes, mixed gently by swirling on ice, and centrifuged at 15,0009g for 20 min at 4°C. The supernatant was used to determine protein concentration by Bradford's method [18] . The protein in different cell lysates (40 lg) was separated on SDS-polyacrylamide gel electrophoresis (PAGE) and electrophoretically transferred on to PVDF membrane. Membrane was blocked with 5 % Carnation fat-free milk for 1 h at room temperature. Antibody [anti-ERa or anti-PR in blocking solution (1:500)] was added and incubated for 1 h, washed and incubated with anti-mouse antibody-HRP (1:500) for ERa and PR proteins, and anti-rabbit antibody-HRP (1:500) for GAPDH protein for 1 h at room temperature. Immunoreactive proteins were visualized using Luminata Forte Western HRP substrate and as per the specifications provided by the supplier in a Syngene Gel Documentation system (MD, USA). Immunoreactive bands were quantified using image analysis software (ImageJ).
Statistical analysis
The MTT assay and the images of semi-quantitative RT-PCR gel data were analyzed by student t test and one-way ANOVA followed by post hoc Tukey test. Values were considered statistically significant if *P \ 0.05, **P \ 0.005 compared to control and from E2-treated samples if # P \ 0.005. In the Estradiol-17b-treated MCF-7 cells, there was a marginal increase in the proliferation at 10 and 50 nM, but showed more than 30 % increase at 100 nM E2. However, the cell number decreases and plateaus off at higher concentrations of 0.5 and 1 lM of E2, respectively (Fig. 1a) . Figure 1b shows that P4 induces proliferation of MCF-7 cells with maximum of 36 % at 150 nM. However, at higher concentrations of P4, the proliferation decreases and plateaus off. When treated with Dex, cell proliferation was decreased marginally in a dose-dependent manner, and there was significant decrease (26 %) at 200 nM (Fig. 1c) . Cells treated with E2 in combination with Dex or P4 in combination with Dex show decreased viability compared to E2-(100 nM) or P4 (150 nM) alone-treated cells (Fig. 1d) . The results suggested that Dex appears to inhibit E2-or P4-induced effects in MCF-7 cells. MTT assay. Results show that the cell viability was decreased in a dose-dependent manner, and a maximum of 20 and 25 % decrease was observed with ICI 182,780 at 10 and 25 nM, respectively. At higher concentrations, the cell number plateaus off (Fig. 2a) . Cell viability was not found to be varied greatly when cells were treated with RU486, but only 10 % decrease in the cell viability was observed with lower concentrations (10 and 50 nM), while a maximum of 15 % decrease in cell viability was observed at 1 lM concentration of the inhibitor (Fig. 2b) .
E2 induces ER, down-regulates PR and GR
MCF-7 cells were treated with E2 (100 nM) or Dex (100 nM) or P4 (150 nM) or E2 (100 nM) in combination with Dex (100 nM) or P4 (150 nM) in combination with Dex (100 nM) for 48 h, and the expression of ERa, PR, and GR mRNAs was analyzed. Results show that the expression of ERa mRNA was significantly induced by all steroid hormone treatments, and a maximum increase of twofold was observed with E2 alone or Dex alone treatment, while P4 alone shows 2.2-fold increase in the expression. Whereas, the cells treated with Dex along with E2 or P4 show significant decrease in the expression of ERa mRNA compared to E2 and P4 alone treatments, and ERb mRNA was found to be less expressed in all the treatments (data not shown). Analysis of PR mRNA shows that E2 and Dex alone or in combination decreased the expression compared to control, while P4 alone shows marginal decrease in PR expression. Whereas, analysis of expression of GR mRNAs shows that the Dex or P4 alone or in combination induced the expression by 2.5-, 2-and 2-fold, respectively, while E2 treatment shows significant decrease in the expression by more than 80 % compared to control. Cells treated with Dex in combination with E2 show significant decrease in the expression of GR mRNAs compared to Dex alone-treated cells (Fig. 3a) . MCF-7 cells treated with steroid hormones in combination with ICI 182,780 or RU486 for 48 h show the variable expression pattern of mRNAs of steroid receptors. Cells treated with E2 and ICI decreased ERa expression by 58 % compared to control. However, Dex and RU486 show 1.4-fold increase in the ERa mRNA expression, while cells treated with P4 and RU486 show no change in the expression of ERa mRNA compared to control. The cells treated with E2 and ICI or Dex and RU486 show 2.8-and 2.5-fold increase in PR mRNA expression, respectively, compared to control. But the cells treated with P4 and RU486 shows 62 and 58 % decrease in PR, respectively, compared to cells treated with E2 and ICI or Dex and RU486. Meanwhile, Dex and RU486, and P4 and RU486 show 70 and 79 % decrease in GR mRNA expression, respectively, compared to E2-and ICI-treated cells. But there is less or no change in PR expression in the cells treated with P4 and RU486 compared to control (Fig. 3b) .
E2 induces ERa protein, and Dex down-regulates ERa and PR protein levels
MCF-7 cells treated with E2 alone show significant increase in ERa protein level by more than 20 % compared to control, and Dex found to reduce ERa protein by more than 50 and 68 %, respectively, when treated alone and in (100 nM) or Dex (100 nM) or P4 (150 nM) or E2 (100 nM) and Dex (100 nM) or P4 (150 nM) and Dex (100 nM) or E2 (100 nM) and ICI (10 nM) or Dex (100 nM) and RU486 (10 nM) or P4 (150 nM) and RU486 (10 nM) for 48 h, and expression of mRNAs of steroid receptors was measured by semi-qRT-PCR technique. For immunoblotting, the cells were treated with E2 (100 nM) or Dex (100 nM) or P4 (150 nM) or E2 (100 nM) and Dex (100 nM) or P4
(150 nM) and Dex (100 nM) for 48 h. Cell lysates were prepared using lysis buffer, and equal amount of protein (40 lg) containing cell lysates were separated by SDS-PAGE, transferred to PVDF membrane, and analyzed by immunoblotting using ERa, PR, and GAPDH antibodies. The expressed protein level of GAPDH was used as a control. Data presented as mean ± SD, n = 3. Differences in the expression of mRNAs or protein levels are statistically significant: if *P \ 0.05 compared with controls, # P \ 0.05 compared with E2-induced values, and **P \ 0.005 compared with P4-induced values, using one-way ANOVA followed by post hoc Tukey test. The bar graph represents the densitometric analysis of mRNAs or protein levels combination with E2 compared to E2 alone-treated cells. Similarly, Dex found to reduce PR protein level by 25 and 27 %, respectively, when treated alone and in combination with P4 compared to P4 alone-treated cells (Fig. 3c) .
Dex down-regulates E2-or P4-induced AP-1 mRNAs
In order to study the combinatorial effect of steroid hormones, MCF-7 cells were treated with or without steroid hormones (E2 or Dex or P4 or E2 and Dex or P4 and Dex or E2 and P4 or E2 and P4 and Dex) or steroid hormones in combination with antagonists (E2 and ICI or Dex and RU486 or P4 and RU486) for 48 h, and the differential expression pattern of AP1 mRNAs were measured by semiq-RT-PCR, and relative mRNA levels were analyzed. The results show that the cells treated with E2 significantly induced the expression of c-Jun, Fra-1 by 1.8-and 1.7-fold, respectively, compared to control. However, the cells treated with P4 also show induced expression of c-Jun, while Dex decreased the expression of c-Jun, Fra-1, and Fra-2 when used in combination with E2 compared to E2 alone-treated cells (Fig. 4a) . The results depicted in Fig. 4b show that in the cells treated with both E2 and P4, there was a significant increase in the expression of mRNAs of c-Jun by 2.7-fold, c-Fos by 2.75-fold, Fra-1 and Fra-2 mRNAs by 1.5-fold compared to control. Cells treated with Dex along with E2 and P4 reduced the expression of mRNAs of c-Jun and Fra-2 by 61 and 20 %, respectively, compared to E2-and P4-treated cells. Further, marginal reduction in the c-Fos and Fra-1 mRNAs suggested that P4 appears to have synergistic effect with E2, while Dex has antagonistic effect of E2 in MCF-7 cells (Fig. 4b) .
MCF-7 cells treated with E2 in combination with antagonist of E2 show that ICI significantly reduced the expression of c-Jun, c-Fos, and Fra-1 mRNAs by 75, 49.5, and 67 %, respectively, compared to control, and the cells treated with P4 and RU486 show that the expression of c-Fos and Fra-1 mRNAs were decreased by 20 and 70 %, respectively. Whereas, in the cells treated with Dex and RU486, Fra-1 mRNA level was significantly reduced, and there was little or no effect on the expression of mRNAs of c-Jun and c-Fos, but Fra-2 mRNA was significantly induced by 5.7-fold compared to control. The results suggest that RU486 being an antagonist blocking the action of Dex, and hence it induced the expression of Fra-2 mRNA in MCF-7 cells (Fig. 4c) .
Discussion
In mammals, the development and differentiation of mammary gland are regulated by sex steroid hormones (estrogen and progesterone) produced by the developing ovary. The development of the gland also depends on physical, molecular, and often reciprocal interactions of stromal and epithelial compartments [19] . Steroid hormones such as estrogen, progesterone including glucocorticoids cross-talk to exhibit variable transcriptional responses in mammary gland development. Over-expression of some of the early oncogenes such as AP-1 factors probably results in the development of breast cancer. Mechanism of cross-talk between the steroid hormones, their receptors, and role of AP-1 proteins in the development of cancer are yet to be understood. Hence, the present study was undertaken to understand the role of ER and PR including GR in the regulation of the expression of AP-1 Fig. 4 Effect of a Steroid hormones (E2 or Dex or P4) or (b) steroid hormones in combination (E2 and P4 or E2 and P4 and Dex), or (c) steroid hormones in combination with their antagonists (E2 and ICI or Dex and RU486 or P4 and RU486) on the expression of AP-1 factors in MCF-7 cells. Cells were treated with or without steroid hormones (E2 or Dex or P4) or in combination (E2 and Dex or P4 and Dex or E2 and P4 or E2, P4 and Dex), or with steroid hormone antagonists (E2 and ICI or Dex and RU486 or P4 and RU486) for 48 h. Total RNA was isolated, and AP1 factors were analyzed on 1 % agarose gel. Data presented as mean ± SD, n = 3. Values are significantly different in figure (a) from the control if **P \ 0.05 and **P \ 0.05 and from E2 alone if # P \ 0.005, in figure (b) *P \ 0.05 from E2 and P4 samples, and in figure (c) if *P \ 0.05 from control and if **P \ 0.05 from steroid hormones and antagonists-treated samples using one-way ANOVA followed by post hoc Tukey test. The results are shown as representative of three independent experiments factors. In most of the breast cancers, the cells are found to be triple positive (ER, PR, and GR responsive), and at later point of time lose the expression of receptors and become much more aggressive tumors. MCF-7 cells used in our study were found to be triple positive as ER, GR, and PR mRNAs were expressed, and hence used to understand the cross-talk between the steroid hormones and their receptors. Both E2 and P4 at physiological concentration induce proliferation. Our study also shows that both E2 and P4 induce the expression of ERa at mRNA and protein levels, and proliferation is through the steroid receptor ERa. P4 potentially induces ERa at mRNA level, but the effect was less seen at protein level. However, the expression of ERb mRNA was negligible (data not shown) confirming our earlier studies [14] . Studies carried out in different laboratories suggested that ERa-positive cells induced by E2 release paracrine growth factors such as EGF which mediates ERa-mediated mammary gland epithelial cell proliferation. We also found that with increase in the dose of E2 in the treatment of MCF-7 cells, the proliferation was increased [20] .
MCF-7 cells express all the three NRs (ERa, PR, and GR); as the NRs and their hormones are closely related, there is every possibility of extensive interplay and downstream signaling. It is a well-known fact that the combinatorial expression of all the NRs is important in determining the prognosis and avenues for the treatment [21, 22] . However, fewer studies have been carried out on the expression of all the steroid hormone receptors by examining the action of one hormone at a time, and mostly a reductionist approach was used [23] . Studies using GR with PR [24, 25] or ERa with RAR [26, 27] show both competitive and co-operative interactions. Hence, in our studies, the expression of all the three NRs (ERa, PR, and GR) was examined for the action of E2 or Dex or P4 alone or in combination of E2 with Dex or P4 with Dex. Our studies show that all the steroid hormones (E2 or P4 or Dex) induced the expression of ERa; however, combination of E2 or P4 with Dex reduced ERa expression, suggesting that the proliferation or anti-proliferative effect may be through ERa. P4 also stimulates the proliferation, and probably the action is through ERa as earlier studies have shown that the steroid action is through ERa in MCF-7 cells [28] . Dex reduces the cell proliferation and shows opposing effect of E2 in MCF-7 cells. Buxant et al. [29] showed that concentration of Dex as low as 10 -7 M reduced the proliferation of MCF-7 cells by more than 30 % [29] . Several studies also demonstrated the antagonistic effect of estrogen by glucocorticoids in ER/GR-positive breast and uterine carcinoma cells. Using multiple estrogen-responsive transcriptional assay system, steroid receptor co-activators (SRC 2, SRC 3) with MED 14 (mediator component); it was found that GR recruits five-time ER transcriptional responses under multiple hormone stimuli using GFP-ERa, HeLa-PRL cells [23] . Dex counteracts the stimulatory effect of E2 on MCF-7 cells and inhibits cell proliferation, and the down-regulation of ER by GCs is by attenuation and not by negative response. The inhibitory action of Dex on the estradiol-induced cell proliferation was confirmed by thymidine incorporation into DNA in MCF-7 cells [30] .
When both E2 and Dex hormones were added simultaneously, estradiol-stimulated transcription of genes was found to be blocked by glucocorticoid hormone. Studies show that Dex occupies several ER-binding regions (EBR), and little or less sites are available for E2 binding to its receptor ERa [8] . Further, with increasing the duration of exposure time of Dex to MCF-7 cells, the GR predominantly localized in the nucleus binding to ERa. Probably, this may be the reason for the receptor ERa to become available more for Dex and less for E2 or P4, so that E2-or P4-mediated transcriptional processes found to be downregulated. The mechanism of E2 regulation by GR and vice versa is yet to be completely understood. Krishnan et al. [31] demonstrated that E2 treatment causes substantial suppression of GR mRNA and protein levels [31] . In our study also E2 down-regulated the expression of GR, as the cells were exposed longer to E2. Our studies on the expression pattern of ER, PR, and GR mRNAs in MCF-7 cells with different steroid hormone treatments and in combination show that E2, P4, and Dex alone induce ERa mRNA, while Dex down-regulated E2-or P4-induced ERa at both mRNA and protein levels. Thus, Dex attenuates E2 responses, but the mechanism by which GC inhibits the E2 activity is not completely understood. However, earlier study showed that Dex induced and activated the estrogen sulfotransferase enzyme activity that sulfonate E2, and sulfonated E2 cannot bind and activate ER-and E2-mediated genes. In the presence of E2, Dex recruits GR binds to ERa binding region and destabilizes ERa transcriptional complex [32] . Thus, Dex inhibits E2-dependent proliferation and down-regulates the ERa-regulated target genes. Earlier studies also show that Dex has stimulatory effect in solid tumors including MCF-7 cells. In general, GCs use two mechanisms to do so: an anti-apoptotic, prosurvival action combined with a pro-proliferative action [33] which supports our studies, where Dex induces ERa mRNA expression that is involved in proliferation. In our studies, RU486 exerts both anti-progestin and anti-glucocorticoid activity by reducing the expression of both GR and PR mRNAs. Although RU486 is an anti-progestin, the inhibitor was found to be more effective towards the expression of GR mRNA compared to PR mRNA when used along with Dex. Further, we demonstrated that RU486 treatment along with Dex or P4 increased ERa mRNA suggesting that the suppression of GR mRNA has a positive effect on the expression. This further confirms the interplay of GR and ER.
In our study, all the steroid hormone treatments reduced the expression of PR mRNA as well as PR protein which suggested that E2 or Dex may compete for PR-binding regions like in the case of ER binding with more affinity, and hence PR sites are less available for progesterone binding, resulting in reducing the expression of PR and that needs further investigation. However, P4 reduced the expression of PR mRNA, and less effect was observed at PR protein level. This is probably due to P4 binding to ERa or GR dimerization of PR that may have resulted because of the constant exposure. Earlier studies show that the expression of PR is independent of E2 expression in T-47D breast cancer cells. Estrogen-pre-treated breast cancer cells show tenfold induction in PR levels than those with estrogen-nontreated cells. It is difficult to study the intrinsic biological role of PR in breast cancers precisely because of its inter-dependent relationship on ERa and concordance between the levels of ER and PR in breast cancers [34] [35] [36] . PR action is dependent on the hormonal context with concurrent estrogen treatment producing a unique transcriptomic response to progesterone. The master regulator of progesterone response in breast cancer appears to be estrogen dependent which regulates PR abundance, thereby permitting PR-DNA binding, which suggests that the action of estrogen and progesterone is inextricably linked. ER and PR have the longest co-existence in relation to other receptors such that ERa-mediated up-regulation of PR abundance permits activity in response to progesterone, and PR in turn regulates a subset of ERa actions [28, 37, 38] .
Our study also show that the MCF-7 cells treated with E2 increased the expression of mRNAs of c-Jun, c-Fos, and Fra-1, confirming our previous observation [14] , while P4 appears to have induced effect on the expression of c-Jun and Fra-1 mRNAs. This confirms that P4 has E2-like effects. However, cells treated with E2 and Dex show significant decrease in c-Jun and c-Fos expression, suggesting that the Dex inhibits E2-induced expression specifically and may play a major role in proliferation. E2 together with P4 induces the expression of c-Jun/c-Fos and Fra-2, suggesting the synergistic action of ER and PR, further confirming that P4 acts like E2 [39, 40] . However, Dex inhibited the expression of c-Jun, c-Fos, and Fra-2 induced by E2 and P4, and suggested the antagonistic effect of Dex. Use of ICI proves the role of E2 in the expression of c-Jun, c-Fos, and Fra-1 mRNAs. Dex and RU486 induced Fra-2 by more than fivefold, and this may be probably due to blocking of Dex action through GR or PR that needs to be investigated. Previous studies show that the ratio of Jun:Fos (c-Jun:c-Fos or Jun-D:c-Fos or Jun-D:Fra-1) in a given cell changes the steroid response to Dex at AP-1 site and proliferin complex (GRE/AP-1) response element. The result of our study suggested that ER, PR, and GR play a major role in the proliferation of cells through c-Jun, c-Fos, and fra-1 AP-1 factors.
In conclusion, our study suggested that breast cancer cells express ER, PR, and GR, and there exist extensive cross-talk between them through steroid hormones. Thus, glucocorticoids and related compounds can be used as antiestrogenic and anti-progesterone agents in the multi-hormone therapy and in the treatment of breast cancer.
